Last reviewed 2026-06-10 · How we verify

Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine — Treatment Landscape & Competitive Intelligence

Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Pha

Marketed treatment landscape

Approved drugs treating Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine:

• Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine treatment updates — RSS
• Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine treatment updates — Atom
• Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine treatment updates — JSON

Cite this brief

Drug Landscape (2026). Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-who-have-previously-received-primary-vaccination-with-any-authorized-covid-19-vaccine-and-have-previously-received-a-booster-dose-of-any-authorized-covid-19-vaccine. Accessed 2026-06-10.

Related

• Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing